| ORIGINAL ARTICLE |
|
| Year : 2022 | Volume
: 20
| Issue : 3 | Page : 287-293 |
|
|
Short-term effects of prophylactic intravitreal injection of triamcinolone and moxifloxacin combination after cataract surgery
Emad A.A Saliem
Department of Ophthalmology, Al-Azhar Faculty of Medicine, Assiut, Egypt
Correspondence Address:
MD Emad A.A Saliem
Tahta, Sohag 71524
Egypt
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/azmj.azmj_1_22
|
|
|
Background and Aim To evaluate the short-term effects and safety of prophylactic intravitreal injection of triamcinolone–moxifloxacin combination after cataract surgery.
Patients and methods This study included 100 eyes of 84 patients who underwent cataract surgery associated with intravitreal injection of triamcinolone–moxifloxacin combination after surgery. The patients were re-assessed at the first day, first week, and then monthly up to 3 months after surgery. The outcome measures included unplanned use of topical anti-inflammatory or anti-infective drugs during the postoperative period, best-corrected visual acuity (BCVA), and intraocular pressure (IOP). The mean age of patients was 55.99±5.20 years.
Results The mean BCVA showed a statistically significant difference between the preoperative and the postoperative values, where the mean BCVA improved from 1.21±0.27 logMAR before operation to 0. 83±0.25 logMAR at the first week, 0.46±0.21 logMAR at the first month, and 0.19±0.14 logMAR at the third month. The mean IOP revealed no statistically significant differences between preoperative and postoperative values at the end of the first month (P<0.084). The preoperative IOP ranged from 12 to 19 mmHg, with an average of 15.35±1.60 mmHg and became 14.52±1.11 mmHg at the end of the first month after surgery. There was no evidence of postoperative complications such as endophthalmitis or other complications such as retinal detachment and vitreous hemorrhage.
Conclusion Intravitreal injection of triamcinolone–moxifloxacin combination after cataract surgery can be used as an alternative to medications applied topically for prophylaxis against postoperative complications associated with cataract surgery such as infection and inflammation.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
![JOURNAL_FULL_NAME]](images/logo.gif){kind=logo}
